Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2016 1
2018 1
2019 1
2020 1
2021 2
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Ávila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodríguez de la Concepción ML, Pedreño-Lopez N, Rodon J, Urrea V, Pradenas E, Marfil S, Ballana E, Riveira-Muñoz E, Pérez M, Roca N, Tarrés-Freixas F, Cantero G, Pons-Grífols A, Rovirosa C, Aguilar-Gurrieri C, Ortiz R, Barajas A, Trinité B, Lepore R, Muñoz-Basagoiti J, Perez-Zsolt D, Izquierdo-Useros N, Valencia A, Blanco J, Guallar V, Clotet B, Segalés J, Carrillo J. Ávila-Nieto C, et al. Among authors: aguilar gurrieri c. Nat Commun. 2024 Mar 21;15(1):2349. doi: 10.1038/s41467-024-46714-w. Nat Commun. 2024. PMID: 38514609 Free PMC article.
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A, Amengual-Rigo P, Pons-Grífols A, Ortiz R, Gracia Carmona O, Urrea V, de la Iglesia N, Blanco-Heredia J, Anjos-Souza C, Varela I, Trinité B, Tarrés-Freixas F, Rovirosa C, Lepore R, Vázquez M, de Mattos-Arruda L, Valencia A, Clotet B, Aguilar-Gurrieri C, Guallar V, Carrillo J, Blanco J. Barajas A, et al. Among authors: aguilar gurrieri c. J Transl Med. 2024 Jan 3;22(1):14. doi: 10.1186/s12967-023-04843-8. J Transl Med. 2024. PMID: 38172991 Free PMC article.
Production of HIV-1-based virus-like particles for vaccination: achievements and limits.
Cervera L, Gòdia F, Tarrés-Freixas F, Aguilar-Gurrieri C, Carrillo J, Blanco J, Gutiérrez-Granados S. Cervera L, et al. Among authors: aguilar gurrieri c. Appl Microbiol Biotechnol. 2019 Sep;103(18):7367-7384. doi: 10.1007/s00253-019-10038-3. Epub 2019 Aug 1. Appl Microbiol Biotechnol. 2019. PMID: 31372703 Review.
New emerging targets in cancer immunotherapy: the role of neoantigens.
De Mattos-Arruda L, Blanco-Heredia J, Aguilar-Gurrieri C, Carrillo J, Blanco J. De Mattos-Arruda L, et al. Among authors: aguilar gurrieri c. ESMO Open. 2020 Apr;4(Suppl 3):e000684. doi: 10.1136/esmoopen-2020-000684. ESMO Open. 2020. PMID: 32269031 Free PMC article. Review.
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Trinité B, Durr E, Pons-Grífols A, O'Donnell G, Aguilar-Gurrieri C, Rodriguez S, Urrea V, Tarrés F, Mane J, Ortiz R, Rovirosa C, Carrillo J, Clotet B, Zhang L, Blanco J. Trinité B, et al. Among authors: aguilar gurrieri c. Vaccine. 2024 May 31;42(15):3474-3485. doi: 10.1016/j.vaccine.2024.04.048. Epub 2024 Apr 18. Vaccine. 2024. PMID: 38641492 Free article.
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization.
Pradenas E, Marfil S, Urrea V, Trigueros M, Pidkova T, Pons-Grífols A, Ortiz R, Rovirosa C, Tarrés-Freixas F, Aguilar-Gurrieri C, Toledo R, Chamorro A, Noguera-Julian M, Mateu L, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Trinité B, Blanco J. Pradenas E, et al. Among authors: aguilar gurrieri c. iScience. 2023 Apr 21;26(4):106457. doi: 10.1016/j.isci.2023.106457. Epub 2023 Mar 20. iScience. 2023. PMID: 36999095 Free PMC article.
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.
Ortiz R, Barajas A, Pons-Grífols A, Trinité B, Tarrés-Freixas F, Rovirosa C, Urrea V, Barreiro A, Gonzalez-Tendero A, Cardona M, Ferrer L, Clotet B, Carrillo J, Aguilar-Gurrieri C, Blanco J. Ortiz R, et al. Among authors: aguilar gurrieri c. Int J Mol Sci. 2023 May 19;24(10):9025. doi: 10.3390/ijms24109025. Int J Mol Sci. 2023. PMID: 37240371 Free PMC article.
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.
Tarrés-Freixas F, Aguilar-Gurrieri C, Rodríguez de la Concepción ML, Urrea V, Trinité B, Ortiz R, Pradenas E, Blanco P, Marfil S, Molinos-Albert LM, Barajas A, Pons-Grífols A, Ávila-Nieto C, Varela I, Cervera L, Gutiérrez-Granados S, Segura MM, Gòdia F, Clotet B, Carrillo J, Blanco J. Tarrés-Freixas F, et al. Among authors: aguilar gurrieri c. NPJ Vaccines. 2023 Apr 6;8(1):51. doi: 10.1038/s41541-023-00648-4. NPJ Vaccines. 2023. PMID: 37024469 Free PMC article.
17 results